FUNDAMENTALS · Fundamentals · US Healthcare

Crescent Biopharma (CBIO) Fundamentals 2026 — Revenue Analysis | SniperIQ

Crescent Biopharma (CBIO) is a US-listed Healthcare company in Biotechnology with a market capitalization of $431M, trading at

5.63 on the NASDAQ. This SniperIQ fundamentals page covers Crescent Biopharma's valuation, profitability (net margin -1363.9%), revenue (
1M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$431M
Net Margin-1363.9%
Revenue (FY25)
1M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Crescent Biopharma's market cap?

Crescent Biopharma (CBIO) has a market capitalization of approximately $431M, trading at

5.63 on the NASDAQ. Market cap moves with the live share price.

What is Crescent Biopharma's P/E ratio?

Crescent Biopharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Crescent Biopharma?

Crescent Biopharma runs a net profit margin of -1363.9%, a gross margin of 100.0%, and an operating margin of -1372.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Crescent Biopharma generate?

Crescent Biopharma reported revenue of

1M for fiscal year 2025, with net income of -
54M and earnings per share (EPS) of -14.78. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Crescent Biopharma pay a dividend?

Crescent Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Crescent Biopharma financially healthy?

Crescent Biopharma carries a debt-to-equity ratio of 0.01x and a current ratio of 13.78x, with a market beta of 1.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Crescent Biopharma a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Crescent Biopharma (CBIO) the key facts are: market cap $431M, revenue

1M, 52-week range 8.72-27.41. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Crescent Biopharma's full fundamentals live

Get Crescent Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Claritev (CTEV) fundamentals · iX Biopharma (42C) fundamentals · Pacific Biosciences of California (PACB) fundamentals · Anteris Technologies (AVR) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons